Zealand Pharma A/S (ZEAL) Reaches New 52-Week Low at $12.48

Shares of Zealand Pharma A/S (NASDAQ:ZEAL) hit a new 52-week low during trading on Wednesday . The stock traded as low as $12.48 and last traded at $12.65, with a volume of 2200 shares trading hands. The stock had previously closed at $12.75.

Several analysts recently commented on the company. Needham & Company LLC assumed coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued a “buy” rating and a $26.00 price target on the stock. Guggenheim assumed coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued a “buy” rating and a $28.00 price target on the stock. Morgan Stanley assumed coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued an “overweight” rating and a $28.00 price target on the stock. Goldman Sachs Group assumed coverage on Zealand Pharma A/S in a research note on Wednesday, September 27th. They issued a “buy” rating on the stock. Finally, Zacks Investment Research raised Zealand Pharma A/S from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Wednesday, November 15th. Five research analysts have rated the stock with a buy rating, Zealand Pharma A/S currently has an average rating of “Buy” and an average target price of $24.75.

Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in Zealand Pharma A/S in the third quarter worth $386,000. Royce & Associates LP acquired a new position in Zealand Pharma A/S in the third quarter worth $1,152,000. Finally, Susquehanna International Group LLP acquired a new position in Zealand Pharma A/S in the third quarter worth $3,185,000. 13.33% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/22/zealand-pharma-as-zeal-reaches-new-52-week-low-at-12-48.html.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

What are top analysts saying about Zealand Pharma A/S? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zealand Pharma A/S and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit